Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

The women had early stage breast cancer that was HR-positive and HER2-negative. When compared to chemotherapy, the ribociclib and letrozole were found to be just as effective and better tolerated.

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

As a health and medical reporter, I've covered a steady drumbeat of headlines about the alarming uptick in breast cancer cases among adults in their 20s, 30s and 40s. I've read the studies.

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

When Jamie LaScala turned 40 in 2015, she didn't think she needed a mammogram just yet, but a friend encouraged her to go. “I was right on the cusp of when you’re supposed to start getting the ...

Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The decrease was primarily due to the recognition of previously received milestone ...